BR112020023252A2 - composição do agente terapêutico e método de uso para tratamento de deficiência cognitiva leve, depressão e distúrbios psicológicos. - Google Patents

Info

Publication number

BR112020023252A2

BR112020023252A2 BR112020023252-1A BR112020023252A BR112020023252A2 BR 112020023252 A2 BR112020023252 A2 BR 112020023252A2 BR 112020023252 A BR112020023252 A BR 112020023252A BR 112020023252 A2 BR112020023252 A2 BR 112020023252A2

Authority

BR

Brazil

Prior art keywords

cyclic

disease

cpg

proline

glycyl

Prior art date

2018-05-15

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 153
• 238000011282 treatment Methods 0.000 title claims abstract description 95
• 208000010877 cognitive disease Diseases 0.000 title claims abstract description 85
• 239000000203 mixture Substances 0.000 title claims abstract description 54
• 208000020016 psychiatric disease Diseases 0.000 title claims abstract description 41
• 208000027061 mild cognitive impairment Diseases 0.000 title claims description 35
• 239000003814 drug Substances 0.000 title abstract description 62
• 229940124597 therapeutic agent Drugs 0.000 title abstract description 5
• 125000004122 cyclic group Chemical group 0.000 claims abstract description 290
• RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 claims abstract description 154
• 108010029020 prolylglycine Proteins 0.000 claims abstract description 154
• 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 131
• 208000018737 Parkinson disease Diseases 0.000 claims abstract description 33
• 230000004770 neurodegeneration Effects 0.000 claims abstract description 30
• 230000006735 deficit Effects 0.000 claims abstract description 27
• 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
• 208000023105 Huntington disease Diseases 0.000 claims abstract description 19
• 230000002265 prevention Effects 0.000 claims abstract description 15
• 206010008118 cerebral infarction Diseases 0.000 claims abstract description 13
• 206010021143 Hypoxia Diseases 0.000 claims abstract description 12
• 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 11
• 208000012902 Nervous system disease Diseases 0.000 claims abstract description 10
• 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 10
• 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 9
• 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 9
• 239000004090 neuroprotective agent Substances 0.000 claims abstract description 7
• 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 4
• 150000001875 compounds Chemical class 0.000 claims description 181
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 111
• 206010012289 Dementia Diseases 0.000 claims description 94
• 241000124008 Mammalia Species 0.000 claims description 94
• 201000010099 disease Diseases 0.000 claims description 89
• 208000014674 injury Diseases 0.000 claims description 88
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 86
• 230000006378 damage Effects 0.000 claims description 79
• 208000027418 Wounds and injury Diseases 0.000 claims description 78
• 208000024891 symptom Diseases 0.000 claims description 61
• RNHDNNDNSYJUMK-QMMMGPOBSA-N (2s)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@]1(C)CCCN1C(=O)CN RNHDNNDNSYJUMK-QMMMGPOBSA-N 0.000 claims description 56
• 210000002569 neuron Anatomy 0.000 claims description 51
• 210000004027 cell Anatomy 0.000 claims description 43
• 208000028698 Cognitive impairment Diseases 0.000 claims description 39
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 34
• 208000026139 Memory disease Diseases 0.000 claims description 32
• 208000000044 Amnesia Diseases 0.000 claims description 31
• 210000003169 central nervous system Anatomy 0.000 claims description 31
• 210000004556 brain Anatomy 0.000 claims description 30
• 230000001537 neural effect Effects 0.000 claims description 30
• 210000004498 neuroglial cell Anatomy 0.000 claims description 30
• 230000006984 memory degeneration Effects 0.000 claims description 29
• 208000023060 memory loss Diseases 0.000 claims description 29
• 230000004766 neurogenesis Effects 0.000 claims description 29
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 28
• 230000002792 vascular Effects 0.000 claims description 27
• 239000003981 vehicle Substances 0.000 claims description 27
• 230000037396 body weight Effects 0.000 claims description 25
• 230000007850 degeneration Effects 0.000 claims description 25
• 239000002775 capsule Substances 0.000 claims description 23
• 230000001054 cortical effect Effects 0.000 claims description 23
• 230000003412 degenerative effect Effects 0.000 claims description 23
• 208000009829 Lewy Body Disease Diseases 0.000 claims description 22
• 201000002832 Lewy body dementia Diseases 0.000 claims description 22
• 206010036631 Presenile dementia Diseases 0.000 claims description 22
• 208000035475 disorder Diseases 0.000 claims description 22
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 22
• 206010039966 Senile dementia Diseases 0.000 claims description 21
• 230000008929 regeneration Effects 0.000 claims description 20
• 238000011069 regeneration method Methods 0.000 claims description 20
• 230000015572 biosynthetic process Effects 0.000 claims description 19
• 239000002671 adjuvant Substances 0.000 claims description 18
• 239000000969 carrier Substances 0.000 claims description 16
• 210000001320 hippocampus Anatomy 0.000 claims description 16
• 239000003826 tablet Substances 0.000 claims description 15
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 14
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 14
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 14
• 201000004810 Vascular dementia Diseases 0.000 claims description 14
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 14
• 229960002646 scopolamine Drugs 0.000 claims description 14
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 13
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 13
• 239000008194 pharmaceutical composition Substances 0.000 claims description 13
• 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 12
• 238000001802 infusion Methods 0.000 claims description 12
• 230000003902 lesion Effects 0.000 claims description 12
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 11
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 11
• 239000000654 additive Substances 0.000 claims description 11
• 230000006870 function Effects 0.000 claims description 11
• 210000001519 tissue Anatomy 0.000 claims description 11
• 208000020401 Depressive disease Diseases 0.000 claims description 10
• CWLQUGTUXBXTLF-UHFFFAOYSA-N N-methyl-L-proline monohydrate Natural products CN1CCCC1C(O)=O CWLQUGTUXBXTLF-UHFFFAOYSA-N 0.000 claims description 10
• CWLQUGTUXBXTLF-YFKPBYRVSA-N N-methylproline Chemical compound CN1CCC[C@H]1C(O)=O CWLQUGTUXBXTLF-YFKPBYRVSA-N 0.000 claims description 10
• 230000001713 cholinergic effect Effects 0.000 claims description 10
• 239000007864 aqueous solution Substances 0.000 claims description 9
• 239000011230 binding agent Substances 0.000 claims description 9
• 238000001990 intravenous administration Methods 0.000 claims description 9
• 230000002093 peripheral effect Effects 0.000 claims description 9
• 238000007920 subcutaneous administration Methods 0.000 claims description 9
• 238000001356 surgical procedure Methods 0.000 claims description 9
• 210000000225 synapse Anatomy 0.000 claims description 9
• 230000009529 traumatic brain injury Effects 0.000 claims description 9
• 230000007423 decrease Effects 0.000 claims description 8
• 201000006417 multiple sclerosis Diseases 0.000 claims description 8
• 230000007514 neuronal growth Effects 0.000 claims description 8
• 230000008439 repair process Effects 0.000 claims description 8
• 208000020431 spinal cord injury Diseases 0.000 claims description 8
• 239000004471 Glycine Substances 0.000 claims description 7
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 7
• 239000000443 aerosol Substances 0.000 claims description 7
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
• 208000029028 brain injury Diseases 0.000 claims description 7
• 239000007943 implant Substances 0.000 claims description 7
• 238000007918 intramuscular administration Methods 0.000 claims description 7
• 208000028867 ischemia Diseases 0.000 claims description 7
• 230000002685 pulmonary effect Effects 0.000 claims description 7
• 230000001172 regenerating effect Effects 0.000 claims description 7
• 230000000699 topical effect Effects 0.000 claims description 7
• 230000008733 trauma Effects 0.000 claims description 7
• 206010028980 Neoplasm Diseases 0.000 claims description 6
• 230000007954 hypoxia Effects 0.000 claims description 6
• 230000000302 ischemic effect Effects 0.000 claims description 6
• 230000013016 learning Effects 0.000 claims description 6
• 201000003102 mental depression Diseases 0.000 claims description 6
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
• 206010061216 Infarction Diseases 0.000 claims description 5
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 5
• 210000004351 coronary vessel Anatomy 0.000 claims description 5
• 230000000926 neurological effect Effects 0.000 claims description 5
• 230000003956 synaptic plasticity Effects 0.000 claims description 5
• 102000003678 AMPA Receptors Human genes 0.000 claims description 4
• 108090000078 AMPA Receptors Proteins 0.000 claims description 4
• 201000010374 Down Syndrome Diseases 0.000 claims description 4
• 230000004913 activation Effects 0.000 claims description 4
• 230000032683 aging Effects 0.000 claims description 4
• 239000003153 chemical reaction reagent Substances 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 230000002518 glial effect Effects 0.000 claims description 4
• 230000007574 infarction Effects 0.000 claims description 4
• 206010027175 memory impairment Diseases 0.000 claims description 4
• 230000000750 progressive effect Effects 0.000 claims description 4
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
• 210000000278 spinal cord Anatomy 0.000 claims description 4
• 206010008096 Cerebral atrophy Diseases 0.000 claims description 3
• 102000018899 Glutamate Receptors Human genes 0.000 claims description 3
• 108010027915 Glutamate Receptors Proteins 0.000 claims description 3
• 208000031886 HIV Infections Diseases 0.000 claims description 3
• 208000037357 HIV infectious disease Diseases 0.000 claims description 3
• 208000020358 Learning disease Diseases 0.000 claims description 3
• 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
• 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
• 208000009106 Shy-Drager Syndrome Diseases 0.000 claims description 3
• 208000015114 central nervous system disease Diseases 0.000 claims description 3
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
• 201000003723 learning disability Diseases 0.000 claims description 3
• 230000003959 neuroinflammation Effects 0.000 claims description 3
• 230000007996 neuronal plasticity Effects 0.000 claims description 3
• 231100000189 neurotoxic Toxicity 0.000 claims description 3
• 230000002887 neurotoxic effect Effects 0.000 claims description 3
• 210000002763 pyramidal cell Anatomy 0.000 claims description 3
• 230000008736 traumatic injury Effects 0.000 claims description 3
• 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 2
• 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
• 206010048327 Supranuclear palsy Diseases 0.000 claims description 2
• 206010044688 Trisomy 21 Diseases 0.000 claims description 2
• 230000003935 attention Effects 0.000 claims description 2
• 201000011510 cancer Diseases 0.000 claims description 2
• 210000004558 lewy body Anatomy 0.000 claims description 2
• 208000010125 myocardial infarction Diseases 0.000 claims description 2
• KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 claims 3
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 3
• 108010077515 glycylproline Proteins 0.000 claims 3
• WRBBRKMXTLLAOB-QMMMGPOBSA-N (2r)-2-prop-2-enylpyrrolidine-2-carboxylic acid Chemical compound C=CC[C@@]1(C(=O)O)CCCN1 WRBBRKMXTLLAOB-QMMMGPOBSA-N 0.000 claims 1
• 208000027089 Parkinsonian disease Diseases 0.000 claims 1
• 230000001747 exhibiting effect Effects 0.000 claims 1
• 230000000116 mitigating effect Effects 0.000 claims 1
• 230000002107 myocardial effect Effects 0.000 claims 1
• 230000000250 revascularization Effects 0.000 claims 1
• 230000001149 cognitive effect Effects 0.000 abstract description 17
• 238000004519 manufacturing process Methods 0.000 abstract description 8
• 239000002552 dosage form Substances 0.000 abstract description 6
• 208000025966 Neurological disease Diseases 0.000 abstract description 5
• 230000001684 chronic effect Effects 0.000 abstract description 5
• 206010003497 Asphyxia Diseases 0.000 abstract description 3
• 230000009984 peri-natal effect Effects 0.000 abstract description 3
• 239000001961 anticonvulsive agent Substances 0.000 abstract description 2
• 206010002660 Anoxia Diseases 0.000 abstract 1
• 241000976983 Anoxia Species 0.000 abstract 1
• 230000007953 anoxia Effects 0.000 abstract 1
• 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
• 208000005809 status epilepticus Diseases 0.000 abstract 1
• 241001465754 Metazoa Species 0.000 description 76
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 53
• 229940079593 drug Drugs 0.000 description 51
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 50
• 229940049906 glutamate Drugs 0.000 description 43
• 229930195712 glutamate Natural products 0.000 description 43
• 239000011780 sodium chloride Substances 0.000 description 39
• 239000000243 solution Substances 0.000 description 37
• 238000002474 experimental method Methods 0.000 description 32
• 241000700159 Rattus Species 0.000 description 31
• 230000000694 effects Effects 0.000 description 29
• 230000001225 therapeutic effect Effects 0.000 description 28
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 25
• 239000000902 placebo Substances 0.000 description 24
• 229940068196 placebo Drugs 0.000 description 24
• 238000012360 testing method Methods 0.000 description 24
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 23
• 230000001965 increasing effect Effects 0.000 description 22
• 239000000463 material Substances 0.000 description 22
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
• 238000004458 analytical method Methods 0.000 description 19
• 210000003050 axon Anatomy 0.000 description 19
• 230000015654 memory Effects 0.000 description 18
• 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 17
• 102000005962 receptors Human genes 0.000 description 17
• 108020003175 receptors Proteins 0.000 description 17
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 16
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 15
• 108010038912 Retinoid X Receptors Proteins 0.000 description 15
• 239000000935 antidepressant agent Substances 0.000 description 15
• 108090000623 proteins and genes Proteins 0.000 description 14
• 238000011084 recovery Methods 0.000 description 14
• 102000004127 Cytokines Human genes 0.000 description 13
• 108090000695 Cytokines Proteins 0.000 description 13
• 230000006872 improvement Effects 0.000 description 13
• 230000023105 myelination Effects 0.000 description 13
• DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 13
• 108010050904 Interferons Proteins 0.000 description 12
• 102000014150 Interferons Human genes 0.000 description 12
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
• 229940005513 antidepressants Drugs 0.000 description 12
• -1 cPG Chemical class 0.000 description 12
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
• 208000024714 major depressive disease Diseases 0.000 description 12
• 239000002953 phosphate buffered saline Substances 0.000 description 12
• 108090000765 processed proteins & peptides Proteins 0.000 description 12
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 12
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 11
• 238000012048 forced swim test Methods 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 230000002757 inflammatory effect Effects 0.000 description 11
• 229940079322 interferon Drugs 0.000 description 11
• 102000039446 nucleic acids Human genes 0.000 description 11
• 108020004707 nucleic acids Proteins 0.000 description 11
• 150000007523 nucleic acids Chemical class 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• 238000012216 screening Methods 0.000 description 11
• 206010029350 Neurotoxicity Diseases 0.000 description 10
• 206010044221 Toxic encephalopathy Diseases 0.000 description 10
• 238000000338 in vitro Methods 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 210000004379 membrane Anatomy 0.000 description 10
• 239000012528 membrane Substances 0.000 description 10
• 231100000228 neurotoxicity Toxicity 0.000 description 10
• 230000007135 neurotoxicity Effects 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 238000003786 synthesis reaction Methods 0.000 description 10
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
• 238000012347 Morris Water Maze Methods 0.000 description 9
• 230000001430 anti-depressive effect Effects 0.000 description 9
• 230000003920 cognitive function Effects 0.000 description 9
• 239000003102 growth factor Substances 0.000 description 9
• 210000000944 nerve tissue Anatomy 0.000 description 9
• 150000003839 salts Chemical class 0.000 description 9
• 229960004688 venlafaxine Drugs 0.000 description 9
• 241000699670 Mus sp. Species 0.000 description 8
• 102000006386 Myelin Proteins Human genes 0.000 description 8
• 108010083674 Myelin Proteins Proteins 0.000 description 8
• 208000006011 Stroke Diseases 0.000 description 8
• 230000009471 action Effects 0.000 description 8
• 230000008901 benefit Effects 0.000 description 8
• 230000002490 cerebral effect Effects 0.000 description 8
• 230000008859 change Effects 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 230000007246 mechanism Effects 0.000 description 8
• 210000005012 myelin Anatomy 0.000 description 8
• 230000016273 neuron death Effects 0.000 description 8
• 235000018102 proteins Nutrition 0.000 description 8
• 102000004169 proteins and genes Human genes 0.000 description 8
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
• 210000000130 stem cell Anatomy 0.000 description 8
• 206010010144 Completed suicide Diseases 0.000 description 7
• 238000000576 coating method Methods 0.000 description 7
• 230000003247 decreasing effect Effects 0.000 description 7
• 239000012530 fluid Substances 0.000 description 7
• 230000012010 growth Effects 0.000 description 7
• 238000007912 intraperitoneal administration Methods 0.000 description 7
• 231100000252 nontoxic Toxicity 0.000 description 7
• 230000003000 nontoxic effect Effects 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 108010069514 Cyclic Peptides Proteins 0.000 description 6
• 102000001189 Cyclic Peptides Human genes 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
• 229930006000 Sucrose Natural products 0.000 description 6
• 239000013543 active substance Substances 0.000 description 6
• 230000027455 binding Effects 0.000 description 6
• 230000005779 cell damage Effects 0.000 description 6
• 230000030833 cell death Effects 0.000 description 6
• 208000037887 cell injury Diseases 0.000 description 6
• 150000001923 cyclic compounds Chemical class 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
• 229960002989 glutamic acid Drugs 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 238000012261 overproduction Methods 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 230000002062 proliferating effect Effects 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 239000005720 sucrose Substances 0.000 description 6
• 238000013268 sustained release Methods 0.000 description 6
• 239000012730 sustained-release form Substances 0.000 description 6
• 239000006188 syrup Substances 0.000 description 6
• 235000020357 syrup Nutrition 0.000 description 6
• 208000016192 Demyelinating disease Diseases 0.000 description 5
• 206010012374 Depressed mood Diseases 0.000 description 5
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 108010025020 Nerve Growth Factor Proteins 0.000 description 5
• 241000700157 Rattus norvegicus Species 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 230000007278 cognition impairment Effects 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 235000013922 glutamic acid Nutrition 0.000 description 5
• 239000004220 glutamic acid Substances 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 230000007787 long-term memory Effects 0.000 description 5
• 208000011736 mal de Debarquement Diseases 0.000 description 5
• 239000013580 millipore water Substances 0.000 description 5
• 238000002156 mixing Methods 0.000 description 5
• 210000005036 nerve Anatomy 0.000 description 5
• 210000001178 neural stem cell Anatomy 0.000 description 5
• 230000007511 neuronal proliferation Effects 0.000 description 5
• 230000000324 neuroprotective effect Effects 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 230000008458 response to injury Effects 0.000 description 5
• 210000003491 skin Anatomy 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 4
• 208000030507 AIDS Diseases 0.000 description 4
• 208000019901 Anxiety disease Diseases 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 229920002261 Corn starch Polymers 0.000 description 4
• 206010011971 Decreased interest Diseases 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 108010051696 Growth Hormone Proteins 0.000 description 4
• 241000257303 Hymenoptera Species 0.000 description 4
• 102000038100 NR2 subfamily Human genes 0.000 description 4
• 108020002076 NR2 subfamily Proteins 0.000 description 4
• 239000004698 Polyethylene Substances 0.000 description 4
• 206010040070 Septic Shock Diseases 0.000 description 4
• 102100038803 Somatotropin Human genes 0.000 description 4
• 206010052779 Transplant rejections Diseases 0.000 description 4
• 239000011149 active material Substances 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 230000036506 anxiety Effects 0.000 description 4
• 230000006907 apoptotic process Effects 0.000 description 4
• 210000001130 astrocyte Anatomy 0.000 description 4
• 208000010668 atopic eczema Diseases 0.000 description 4
• 230000003542 behavioural effect Effects 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 239000011248 coating agent Substances 0.000 description 4
• 239000008120 corn starch Substances 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 206010015037 epilepsy Diseases 0.000 description 4
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 4
• 229940093471 ethyl oleate Drugs 0.000 description 4
• 206010016256 fatigue Diseases 0.000 description 4
• 239000000796 flavoring agent Substances 0.000 description 4
• 235000003599 food sweetener Nutrition 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 229960001031 glucose Drugs 0.000 description 4
• 239000000122 growth hormone Substances 0.000 description 4
• 238000001631 haemodialysis Methods 0.000 description 4
• 230000000322 hemodialysis Effects 0.000 description 4
• 230000006698 induction Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 208000037906 ischaemic injury Diseases 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 230000033001 locomotion Effects 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 208000002780 macular degeneration Diseases 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 210000004126 nerve fiber Anatomy 0.000 description 4
• 210000003061 neural cell Anatomy 0.000 description 4
• 230000001272 neurogenic effect Effects 0.000 description 4
• 238000007911 parenteral administration Methods 0.000 description 4
• 238000010647 peptide synthesis reaction Methods 0.000 description 4
• 210000002381 plasma Anatomy 0.000 description 4
• 229920000573 polyethylene Polymers 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
• 230000010410 reperfusion Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 201000000980 schizophrenia Diseases 0.000 description 4
• 230000006403 short-term memory Effects 0.000 description 4
• 210000003625 skull Anatomy 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 230000006886 spatial memory Effects 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 239000003765 sweetening agent Substances 0.000 description 4
• 230000009182 swimming Effects 0.000 description 4
• 210000000115 thoracic cavity Anatomy 0.000 description 4
• MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
• 108010082126 Alanine transaminase Proteins 0.000 description 3
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• 208000024172 Cardiovascular disease Diseases 0.000 description 3
• 241001269524 Dura Species 0.000 description 3
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
• 206010019196 Head injury Diseases 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 102000015336 Nerve Growth Factor Human genes 0.000 description 3
• 208000003435 Optic Neuritis Diseases 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 206010064930 age-related macular degeneration Diseases 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 210000000038 chest Anatomy 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 230000000994 depressogenic effect Effects 0.000 description 3
• 229960003638 dopamine Drugs 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 201000002491 encephalomyelitis Diseases 0.000 description 3
• 230000003492 excitotoxic effect Effects 0.000 description 3
• 231100000063 excitotoxicity Toxicity 0.000 description 3
• 239000000835 fiber Substances 0.000 description 3
• 229940029303 fibroblast growth factor-1 Drugs 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 210000003128 head Anatomy 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 206010022437 insomnia Diseases 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000011835 investigation Methods 0.000 description 3
• 230000006742 locomotor activity Effects 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 210000005171 mammalian brain Anatomy 0.000 description 3
• 230000006996 mental state Effects 0.000 description 3
• 229940053128 nerve growth factor Drugs 0.000 description 3
• 230000000626 neurodegenerative effect Effects 0.000 description 3
• 230000004031 neuronal differentiation Effects 0.000 description 3
• 239000002858 neurotransmitter agent Substances 0.000 description 3
• 210000004248 oligodendroglia Anatomy 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 229940076279 serotonin Drugs 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 210000004872 soft tissue Anatomy 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000000007 visual effect Effects 0.000 description 3
• 210000002417 xiphoid bone Anatomy 0.000 description 3
• 108010059616 Activins Proteins 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• 206010002199 Anaphylactic shock Diseases 0.000 description 2
• 244000105624 Arachis hypogaea Species 0.000 description 2
• WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 206010070545 Bacterial translocation Diseases 0.000 description 2
• 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
• 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
• 241000167854 Bourreria succulenta Species 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• 208000002177 Cataract Diseases 0.000 description 2
• 108091006146 Channels Proteins 0.000 description 2
• PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 2
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
• 208000000094 Chronic Pain Diseases 0.000 description 2
• 208000006154 Chronic hepatitis C Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 229920000742 Cotton Polymers 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 108050003237 Fibroblast growth factor 11 Proteins 0.000 description 2
• 102100028413 Fibroblast growth factor 11 Human genes 0.000 description 2
• 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 2
• 108090000046 Fibroblast growth factor 14 Proteins 0.000 description 2
• 102100035292 Fibroblast growth factor 14 Human genes 0.000 description 2
• 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
• 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
• 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
• 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 108091006027 G proteins Proteins 0.000 description 2
• 102000030782 GTP binding Human genes 0.000 description 2
• 108091000058 GTP-Binding Proteins 0.000 description 2
• 208000007882 Gastritis Diseases 0.000 description 2
• 208000017228 Gastrointestinal motility disease Diseases 0.000 description 2
• 240000001238 Gaultheria procumbens Species 0.000 description 2
• 235000007297 Gaultheria procumbens Nutrition 0.000 description 2
• 208000010412 Glaucoma Diseases 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 241000219146 Gossypium Species 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• 102400001066 Growth hormone-binding protein Human genes 0.000 description 2
• 206010019133 Hangover Diseases 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 208000005176 Hepatitis C Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
• 101001071429 Homo sapiens Metabotropic glutamate receptor 2 Proteins 0.000 description 2
• 206010020710 Hyperphagia Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102100026818 Inhibin beta E chain Human genes 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 108010005714 Interferon beta-1b Proteins 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• 108090000467 Interferon-beta Proteins 0.000 description 2
• 108090000862 Ion Channels Proteins 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 206010026749 Mania Diseases 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 201000009906 Meningitis Diseases 0.000 description 2
• 206010027374 Mental impairment Diseases 0.000 description 2
• 244000246386 Mentha pulegium Species 0.000 description 2
• 235000016257 Mentha pulegium Nutrition 0.000 description 2
• 235000004357 Mentha x piperita Nutrition 0.000 description 2
• 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 2
• 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 2
• 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 208000019695 Migraine disease Diseases 0.000 description 2
• 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 2
• 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 2
• 208000009525 Myocarditis Diseases 0.000 description 2
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
• 229940095474 NMDA agonist Drugs 0.000 description 2
• 102000034570 NR1 subfamily Human genes 0.000 description 2
• 108020001305 NR1 subfamily Proteins 0.000 description 2
• 108020000002 NR3 subfamily Proteins 0.000 description 2
• 102000007072 Nerve Growth Factors Human genes 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 102000004230 Neurotrophin 3 Human genes 0.000 description 2
• 108090000742 Neurotrophin 3 Proteins 0.000 description 2
• 102000003683 Neurotrophin-4 Human genes 0.000 description 2
• 108090000099 Neurotrophin-4 Proteins 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 206010033645 Pancreatitis Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 206010036618 Premenstrual syndrome Diseases 0.000 description 2
• 108700019404 Pro-Gly-Pro- ACTH (4-7) Proteins 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• 208000028017 Psychotic disease Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 102000007562 Serum Albumin Human genes 0.000 description 2
• 108010071390 Serum Albumin Proteins 0.000 description 2
• 244000000231 Sesamum indicum Species 0.000 description 2
• 235000003434 Sesamum indicum Nutrition 0.000 description 2
• 235000000340 Solanum pseudocapsicum Nutrition 0.000 description 2
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 206010044248 Toxic shock syndrome Diseases 0.000 description 2
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
• 206010044541 Traumatic shock Diseases 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 206010064996 Ulcerative keratitis Diseases 0.000 description 2
• 208000024780 Urticaria Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 240000004482 Withania somnifera Species 0.000 description 2
• 235000001978 Withania somnifera Nutrition 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000488 activin Substances 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 125000000217 alkyl group Chemical group 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 238000000540 analysis of variance Methods 0.000 description 2
• 208000003455 anaphylaxis Diseases 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000002424 anti-apoptotic effect Effects 0.000 description 2
• 230000000421 anti-necrotic effect Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 230000036528 appetite Effects 0.000 description 2
• 235000019789 appetite Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000007375 bacterial translocation Effects 0.000 description 2
• 238000009227 behaviour therapy Methods 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 208000010217 blepharitis Diseases 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 108010046910 brain-derived growth factor Proteins 0.000 description 2
• 229950004398 broxuridine Drugs 0.000 description 2
• 239000008366 buffered solution Substances 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 230000002612 cardiopulmonary effect Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 208000009885 central pontine myelinolysis Diseases 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 235000019693 cherries Nutrition 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 230000005796 circulatory shock Effects 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 208000019425 cirrhosis of liver Diseases 0.000 description 2
• 210000003109 clavicle Anatomy 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 230000006999 cognitive decline Effects 0.000 description 2
• 201000007717 corneal ulcer Diseases 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• 238000000354 decomposition reaction Methods 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 210000001787 dendrite Anatomy 0.000 description 2
• 210000001947 dentate gyrus Anatomy 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 230000008451 emotion Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 230000002964 excitative effect Effects 0.000 description 2
• 231100000573 exposure to toxins Toxicity 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 230000035558 fertility Effects 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 108090000047 fibroblast growth factor 13 Proteins 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000000834 fixative Substances 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 238000002695 general anesthesia Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 238000005469 granulation Methods 0.000 description 2
• 230000003179 granulation Effects 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 230000002489 hematologic effect Effects 0.000 description 2
• 208000010710 hepatitis C virus infection Diseases 0.000 description 2
• 238000000265 homogenisation Methods 0.000 description 2
• 235000001050 hortel pimenta Nutrition 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 230000036512 infertility Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 102000028416 insulin-like growth factor binding Human genes 0.000 description 2
• 108091022911 insulin-like growth factor binding Proteins 0.000 description 2
• 108010010648 interferon alfacon-1 Proteins 0.000 description 2
• 229960001388 interferon-beta Drugs 0.000 description 2
• 230000037041 intracellular level Effects 0.000 description 2
• 239000000644 isotonic solution Substances 0.000 description 2
• 206010023332 keratitis Diseases 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 238000009533 lab test Methods 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000008449 language Effects 0.000 description 2
• 210000005240 left ventricle Anatomy 0.000 description 2
• 208000036546 leukodystrophy Diseases 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 231100000863 loss of memory Toxicity 0.000 description 2
• 239000012931 lyophilized formulation Substances 0.000 description 2
• 201000004792 malaria Diseases 0.000 description 2
• 238000002483 medication Methods 0.000 description 2
• 230000003340 mental effect Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229910021645 metal ion Inorganic materials 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 239000003094 microcapsule Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 206010027599 migraine Diseases 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 239000003607 modifier Substances 0.000 description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
• 206010028537 myelofibrosis Diseases 0.000 description 2
• 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 230000007971 neurological deficit Effects 0.000 description 2
• 208000008795 neuromyelitis optica Diseases 0.000 description 2
• 239000003900 neurotrophic factor Substances 0.000 description 2
• 229940032018 neurotrophin 3 Drugs 0.000 description 2
• 229940097998 neurotrophin 4 Drugs 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 239000002687 nonaqueous vehicle Substances 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 210000001331 nose Anatomy 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 210000000956 olfactory bulb Anatomy 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 208000021237 paraquat poisoning Diseases 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 235000020232 peanut Nutrition 0.000 description 2
• 239000000816 peptidomimetic Substances 0.000 description 2
• 206010034674 peritonitis Diseases 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical class O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 238000004321 preservation Methods 0.000 description 2
• 201000011264 priapism Diseases 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 2
• 108010070643 prolylglutamic acid Proteins 0.000 description 2
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
• 229960003415 propylparaben Drugs 0.000 description 2
• 239000004089 psychotropic agent Substances 0.000 description 2
• AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 210000005245 right atrium Anatomy 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000009863 secondary prevention Effects 0.000 description 2
• AFEHBIGDWIGTEH-AQRCPPRCSA-N semax Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C1=CNC=N1 AFEHBIGDWIGTEH-AQRCPPRCSA-N 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 230000000862 serotonergic effect Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 201000002859 sleep apnea Diseases 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 238000010532 solid phase synthesis reaction Methods 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 108010033419 somatotropin-binding protein Proteins 0.000 description 2
• 201000011096 spinal cancer Diseases 0.000 description 2
• 208000014618 spinal cord cancer Diseases 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000011146 sterile filtration Methods 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 201000009032 substance abuse Diseases 0.000 description 2
• 231100000736 substance abuse Toxicity 0.000 description 2
• 208000011117 substance-related disease Diseases 0.000 description 2
• 210000003523 substantia nigra Anatomy 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 2
• 208000016261 weight loss Diseases 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• 210000004885 white matter Anatomy 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• YEECVZDETXGRLF-JYJNAYRXSA-N (2s)-1-(2-aminoacetyl)-n-[2-[(2s)-2-[[2-[(2s)-2-formyl-2,5-dihydropyrrol-1-yl]-2-oxoethyl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]pyrrolidine-2-carboxamide Chemical group NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)NCC(=O)N2[C@@H](C=CC2)C=O)CCC1 YEECVZDETXGRLF-JYJNAYRXSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• QUCFVNGGGFLOES-ACQYNFKHSA-N (4s)-5-[[(2s)-1-[[(2s)-1-[[(2r)-6-amino-1-[[(1s)-1-carboxy-2-phenylethyl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2s)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCS(=O)(=O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 QUCFVNGGGFLOES-ACQYNFKHSA-N 0.000 description 1
• GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
• LERUHVMGZCJXLR-LURJTMIESA-N (8as)-2-methyl-6,7,8,8a-tetrahydro-3h-pyrrolo[1,2-a]pyrazine-1,4-dione Chemical group O=C1N(C)CC(=O)N2CCC[C@H]21 LERUHVMGZCJXLR-LURJTMIESA-N 0.000 description 1
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
• LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
• MGNMVYXIKDNAKK-UHFFFAOYSA-N 3,3-bis(3-fluorophenyl)-n-methylpropan-1-amine;hydron;chloride Chemical compound Cl.C=1C=CC(F)=CC=1C(CCNC)C1=CC=CC(F)=C1 MGNMVYXIKDNAKK-UHFFFAOYSA-N 0.000 description 1
• BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 206010002388 Angina unstable Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000000412 Avitaminosis Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 208000024806 Brain atrophy Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 240000008213 Brosimum alicastrum Species 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 108090000565 Capsid Proteins Proteins 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• 241001608562 Chalazion Species 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 206010009269 Cleft palate Diseases 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 206010012373 Depressed level of consciousness Diseases 0.000 description 1
• 206010054089 Depressive symptom Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 206010052804 Drug tolerance Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• 206010016042 Facial bones fracture Diseases 0.000 description 1
• 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
• 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
• 108050002072 Fibroblast growth factor 16 Proteins 0.000 description 1
• 102100035307 Fibroblast growth factor 16 Human genes 0.000 description 1
• 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 1
• 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
• 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
• 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
• 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
• 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
• 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
• 102100038942 Glutamate receptor ionotropic, NMDA 3A Human genes 0.000 description 1
• 102100038958 Glutamate receptor ionotropic, NMDA 3B Human genes 0.000 description 1
• 101710195174 Glutamate receptor ionotropic, NMDA 3B Proteins 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 102000011714 Glycine Receptors Human genes 0.000 description 1
• 108010076533 Glycine Receptors Proteins 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010021024 Hypolipidaemia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
• 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• 239000007836 KH2PO4 Substances 0.000 description 1
• 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
• 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000018514 Mental disorders due to a general medical condition Diseases 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 235000014435 Mentha Nutrition 0.000 description 1
• 241001072983 Mentha Species 0.000 description 1
• 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
• 229920000715 Mucilage Polymers 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100491224 Mus musculus Ankrd54 gene Proteins 0.000 description 1
• 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 208000027626 Neurocognitive disease Diseases 0.000 description 1
• 206010029333 Neurosis Diseases 0.000 description 1
• 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
• 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
• 206010067482 No adverse event Diseases 0.000 description 1
• 108090000630 Oncostatin M Proteins 0.000 description 1
• 102000004140 Oncostatin M Human genes 0.000 description 1
• 108010038109 Org 2766 Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 208000001431 Psychomotor Agitation Diseases 0.000 description 1
• 206010038743 Restlessness Diseases 0.000 description 1
• 101150054830 S100A6 gene Proteins 0.000 description 1
• 102100035348 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Human genes 0.000 description 1
• 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 206010049771 Shock haemorrhagic Diseases 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 208000032140 Sleepiness Diseases 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 241001419253 Spathiphyllum cochlearispathum Species 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 229920006328 Styrofoam Polymers 0.000 description 1
• 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
• 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 206010069363 Traumatic lung injury Diseases 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 206010047627 Vitamin deficiencies Diseases 0.000 description 1
• HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 108010027834 activity-dependent neurotrophic factor Proteins 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 239000002390 adhesive tape Substances 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 235000013334 alcoholic beverage Nutrition 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000003281 allosteric effect Effects 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 239000003416 antiarrhythmic agent Substances 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 230000000949 anxiolytic effect Effects 0.000 description 1
• 229940005530 anxiolytics Drugs 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
• 229960004046 apomorphine Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009697 arginine Nutrition 0.000 description 1
• 238000013528 artificial neural network Methods 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000003140 astrocytic effect Effects 0.000 description 1
• 239000008228 bacteriostatic water for injection Substances 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 238000003287 bathing Methods 0.000 description 1
• 238000013542 behavioral therapy Methods 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 150000001557 benzodiazepines Chemical class 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 229940021459 betaseron Drugs 0.000 description 1
• 230000002457 bidirectional effect Effects 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 230000005821 brain abnormality Effects 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 208000006752 brain edema Diseases 0.000 description 1
• 230000003925 brain function Effects 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229940077731 carbohydrate nutrients Drugs 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000003198 cerebellar cortex Anatomy 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
• 229960005132 cisapride Drugs 0.000 description 1
• DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
• 238000009535 clinical urine test Methods 0.000 description 1
• 229960004414 clomethiazole Drugs 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 230000003930 cognitive ability Effects 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000006854 communication Effects 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 230000002254 contraceptive effect Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 239000002577 cryoprotective agent Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 108010039058 cyclo(tri(prolylglycyl)) Proteins 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 230000003001 depressive effect Effects 0.000 description 1
• 230000007267 depressive like behavior Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 206010013781 dry mouth Diseases 0.000 description 1
• 230000020595 eating behavior Effects 0.000 description 1
• 238000002283 elective surgery Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000004744 fabric Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000007667 floating Methods 0.000 description 1
• 229960002464 fluoxetine Drugs 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 239000003517 fume Substances 0.000 description 1
• 230000004914 glial activation Effects 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000026781 habituation Effects 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 239000002874 hemostatic agent Substances 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000009808 hippocampal neurogenesis Effects 0.000 description 1
• 210000004295 hippocampal neuron Anatomy 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 235000014304 histidine Nutrition 0.000 description 1
• 239000011539 homogenization buffer Substances 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000002631 hypothermal effect Effects 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 208000009326 ileitis Diseases 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 229940090438 infergen Drugs 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000003978 infusion fluid Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 239000002198 insoluble material Substances 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229960003358 interferon alfacon-1 Drugs 0.000 description 1
• 229960003161 interferon beta-1b Drugs 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 231100000515 lung injury Toxicity 0.000 description 1
• 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 230000004630 mental health Effects 0.000 description 1
• 238000001690 micro-dialysis Methods 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 235000014569 mints Nutrition 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 239000002052 molecular layer Substances 0.000 description 1
• 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 230000003533 narcotic effect Effects 0.000 description 1
• 210000000492 nasalseptum Anatomy 0.000 description 1
• 210000001989 nasopharynx Anatomy 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 210000000478 neocortex Anatomy 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000009207 neuronal maturation Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 238000010855 neuropsychological testing Methods 0.000 description 1
• 230000035771 neuroregeneration Effects 0.000 description 1
• 208000015238 neurotic disease Diseases 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 238000012316 non-parametric ANOVA Methods 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 230000002474 noradrenergic effect Effects 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• 108091008589 nuclear estrogen receptors Proteins 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 235000019645 odor Nutrition 0.000 description 1
• 229940127216 oral anticoagulant drug Drugs 0.000 description 1
• 238000003305 oral gavage Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
• 229940124641 pain reliever Drugs 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000003016 pheromone Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000002985 plastic film Substances 0.000 description 1
• 238000005498 polishing Methods 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 108010011110 polyarginine Proteins 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 238000013105 post hoc analysis Methods 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 210000002442 prefrontal cortex Anatomy 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 239000011253 protective coating Substances 0.000 description 1
• 239000000612 proton pump inhibitor Substances 0.000 description 1
• 229940126409 proton pump inhibitor Drugs 0.000 description 1
• KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
• 229960003908 pseudoephedrine Drugs 0.000 description 1
• 229940001470 psychoactive drug Drugs 0.000 description 1
• 238000001671 psychotherapy Methods 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 235000005828 ramon Nutrition 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
• MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
• 229960003946 selegiline Drugs 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 230000037321 sleepiness Effects 0.000 description 1
• 239000000344 soap Substances 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000013179 statistical model Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000001562 sternum Anatomy 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 239000008261 styrofoam Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 238000009495 sugar coating Methods 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 230000000946 synaptic effect Effects 0.000 description 1
• 230000032312 synaptic target recognition Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 238000012353 t test Methods 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 210000000779 thoracic wall Anatomy 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 230000007723 transport mechanism Effects 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 210000000857 visual cortex Anatomy 0.000 description 1
• 230000016776 visual perception Effects 0.000 description 1
• 230000002618 waking effect Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• 229960004010 zaleplon Drugs 0.000 description 1
• HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
• 229960001475 zolpidem Drugs 0.000 description 1
• ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
• 229960000820 zopiclone Drugs 0.000 description 1